This company has been acquired
Sigilon Therapeutics (SGTX) Stock Overview
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
SGTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Sigilon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.47 |
| 52 Week High | US$28.00 |
| 52 Week Low | US$3.77 |
| Beta | 4.11 |
| 1 Month Change | 5.74% |
| 3 Month Change | 253.47% |
| 1 Year Change | 150.50% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| SGTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.3% | -3.5% | 0.8% |
| 1Y | 150.5% | 32.8% | 20.5% |
Return vs Industry: SGTX exceeded the US Biotechs industry which returned 0.6% over the past year.
Return vs Market: SGTX exceeded the US Market which returned 2.4% over the past year.
Price Volatility
| SGTX volatility | |
|---|---|
| SGTX Average Weekly Movement | 127.6% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SGTX's share price has been volatile over the past 3 months.
Volatility Over Time: SGTX's weekly volatility has increased from 65% to 128% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 62 | Rogerio Coelho | sigilon.com |
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes.
Sigilon Therapeutics, Inc. Fundamentals Summary
| SGTX fundamental statistics | |
|---|---|
| Market cap | US$56.50m |
| Earnings (TTM) | -US$30.24m |
| Revenue (TTM) | US$17.65m |
Is SGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGTX income statement (TTM) | |
|---|---|
| Revenue | US$17.65m |
| Cost of Revenue | US$29.37m |
| Gross Profit | -US$11.71m |
| Other Expenses | US$18.53m |
| Earnings | -US$30.24m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.03 |
| Gross Margin | -66.36% |
| Net Profit Margin | -171.29% |
| Debt/Equity Ratio | 0% |
How did SGTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/15 04:07 |
| End of Day Share Price | 2023/08/10 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sigilon Therapeutics, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Thomas Shrader | BTIG |
| Whitney Ijem | Canaccord Genuity |